BioClinica, a global provider of clinical trial management services, has named Garry Johnson as the new senior vice president and chief technology officer (CTO) of the company.
Johnson is expected to take up the responsibility for the company’s Global Technology Strategy, including developing and implementing BioClinica’s technology plan, overseeing technology investments and ensuring that operational efficiencies are maximised.
Prior to joining BioClinica, Johnson was working for Dendrite International as a senior vice president and global chief technology officer of the company.
Before joining Dendrite, Johnson held leadership positions at Boron Lepore (now Cardinal Health) and AlliedSignal (now Honeywell).
BioClinica CEO Mark Weinstein said that Garry is a proven technology leader with the skills to advance BioClinica’s position in clinical trial management services.
“Adding Garry to the BioClinica team is an important benchmark in our company history. The CTO position creates a global-level perspective focused on technology innovation that is expected to maintain,” Weinstein said.